LTR Pharma Secures US ROXUS Deals and Advances SPONTAN FDA Pathway

US Commercial Framework for ROXUS Secured

LTR Pharma (ASX:LTP) has cemented its US commercial pathway for ROXUS, executing definitive agreements with Shed Holdings and Strive Pharmacy shortly after the 2026 financial year ended. These deals finalize a capital-light model combining exclusive telehealth distribution via Shed's Mavrox platform and nationwide Section 503A pharmacy fulfilment through Strive Pharmacy. Shed has committed to delivering at least 150,000 ROXUS units in the first year, while LTR Pharma retains ownership of the product and intellectual property. This partnership framework positions LTR Pharma to tap into the booming US personalised medicine and compounding pharmacy market, valued at over US$6 billion in 2023 and forecast to approach US$10 billion by 2033.

SPONTAN Phase II Data Bolsters FDA 505(b)(2) Pathway

On the clinical front, LTR Pharma reported encouraging interim Phase II results for SPONTAN, its lead intranasal erectile dysfunction (ED) therapy. The study enrolled 27 healthy males, including 14 aged 65 and above, addressing a key FDA Pre-IND requirement. SPONTAN demonstrated a median time to peak plasma concentration of approximately 10 minutes for a 5 mg intranasal dose, a stark contrast to around 60 minutes for a 20 mg oral vardenafil tablet. The data also showed no drug accumulation after repeated dosing and no serious adverse events, reinforcing SPONTAN’s rapid onset and safety profile. These findings support continued progression towards a pivotal Phase III trial and eventual New Drug Application (NDA) submission under the FDA’s 505(b)(2) regulatory pathway.

Australian Market Momentum and Real-World Evidence

SPONTAN’s Australian footprint continues to expand, with over 1,000 prescriptions dispensed via the Therapeutic Goods Administration’s Special Access Scheme and Authorised Prescriber pathways. This growing prescriber base and repeat prescribing indicate strong clinical uptake and patient interest. Distribution is facilitated through Symbion’s extensive pharmacy network, including more than 600 TerryWhite Chemmart outlets, and a telehealth joint venture with Restorative Health Clinic. Real-world evidence is being bolstered by case series highlighting SPONTAN’s utility in post-prostatectomy patients and men with performance-related ED, underscoring its potential to address unmet needs where oral PDE5 inhibitors fall short.

OROFLOW Expands Platform Beyond Erectile Dysfunction

LTR Pharma is also testing the versatility of its intranasal drug delivery platform beyond men’s health. The investigational therapy OROFLOW, targeting oesophageal motility disorders, received ethics approval for its first clinical study conducted by an independent investigator, Dr Peter Wu, at St George Hospital. OROFLOW aims to offer a rapid, non-invasive alternative to invasive treatments like pneumatic dilation and surgery for conditions that impair swallowing. The global market for oesophageal motility disorders is projected to reach US$8.1 billion by 2034, highlighting the commercial potential of this expansion.

Financials Reflect Investment in Growth and Development

Financially, LTR Pharma reported a statutory loss after tax of A$14.16 million for FY26, widening from A$5.6 million the previous year. The increase reflects ramped-up investment in clinical development, regulatory activities, and commercial preparations, including a significant A$6.7 million spent on research and development, largely focused on SPONTAN’s Phase II programme. Despite the loss, the company maintains a strong balance sheet with A$19.6 million in cash and no debt as of 30 June 2026. Operating cash outflows averaged A$2.8 million per quarter, with a higher spend in the June quarter related to the completion of the SPONTAN Phase II treatment phase.

Strategic Leadership and Advisory Board Enhancements

To support its US ambitions, LTR Pharma strengthened its Scientific Advisory Board with the appointments of two prominent US urologists: Dr Amy Pearlman, co-founder of the Prime Institute in Florida, and Dr Andrew Sun, Director of Men’s Health at Urology Partners of North Texas. Their clinical insights into US prescribing practices and patient behaviour are expected to be instrumental as LTR Pharma scales its US operations. Professor Eric Chung, President of the International Society for Sexual Medicine, and Associate Professor Darren Katz continue to advise from Australia.

Looking Ahead: Execution and Expansion in FY27

Entering FY27, LTR Pharma’s focus is sharply on execution. The company aims to launch ROXUS commercially in the US in the second half of 2026, subject to completion of manufacturing readiness and regulatory requirements. Concurrently, it plans to complete full statistical analysis of SPONTAN’s Phase II data, advance non-clinical toxicology and human factors studies, and prepare for Phase III trials. In Australia, efforts will continue to grow SPONTAN’s prescriber network and patient reach. The OROFLOW programme will progress through its investigator-initiated clinical study, potentially validating the platform’s broader applicability. LTR Pharma also remains open to additional commercial and licensing partnerships to accelerate global expansion of its intranasal delivery technology.